{"transactions":[{"id":940837,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-12T19:06:49.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date."}],"balance_after":17000,"derivative":{"exercise_price":2.01,"expiration_date":"2036-01-09","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001104659-26-002979","document":"tm262917-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1256126/000110465926002979/tm262917-5_4seq1.xml","form_type":"4"}},{"id":1483170,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-11T19:01:14.000Z","date":"2024-06-10","kind":"grant","planned":false,"acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date."}],"balance_after":17000,"derivative":{"exercise_price":1.44,"expiration_date":"2034-06-10","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001104659-24-070516","document":"tm2416928-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1256126/000110465924070516/tm2416928-3_4seq1.xml","form_type":"4"}},{"id":1842591,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-28T17:01:22.000Z","date":"2023-06-26","kind":"grant","planned":false,"acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date."}],"balance_after":17000,"derivative":{"exercise_price":17.52,"expiration_date":"2033-06-26","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001104659-23-075872","document":"tm2319786-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1256126/000110465923075872/tm2319786-4_4seq1.xml","form_type":"4"}},{"id":2259648,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-23T18:49:42.000Z","date":"2022-05-19","kind":"grant","acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date."}],"balance_after":17000,"derivative":{"exercise_price":13.24,"expiration_date":"2032-05-19","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001104659-22-063972","document":"tm2216669-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1256126/000110465922063972/tm2216669-3_4seq1.xml","form_type":"4"}},{"id":2667921,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-15T17:33:18.000Z","date":"2021-06-11","kind":"grant","acquired":true,"shares":14500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full and become exercisable on the earlier of the first anniversary of the grant date or the day immediately prior to the date of the next BioXcel Therapeutics, Inc. annual meeting of stockholders, subject to the Reporting Person's continued service through such vesting date."}],"balance_after":14500,"derivative":{"exercise_price":37.86,"expiration_date":"2031-06-11","underlying":"Common Stock","underlying_shares":14500},"source":{"system":"sec-edgar","filing":"0001104659-21-081587","document":"tm2119762-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1256126/000110465921081587/tm2119762-3_4seq1.xml","form_type":"4"}},{"id":3134874,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-26T16:17:39.000Z","date":"2020-05-21","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full and become exercisable on the earlier of the first anniversary of the grant date or the day immediately prior to the date of the next BioXcel Therapeutics, Inc. annual meeting of stockholders, subject to the Reporting Person's continued service through such vesting date."}],"balance_after":5000,"derivative":{"exercise_price":49.74,"expiration_date":"2030-05-21","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001104659-20-065873","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1256126/000110465920065873/a4.xml","form_type":"4"}},{"id":3134873,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-26T16:17:39.000Z","date":"2020-05-21","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full and become exercisable on the earlier of the first anniversary of the grant date or the day immediately prior to the date of the next BioXcel Therapeutics, Inc. annual meeting of stockholders, subject to the Reporting Person's continued service through such vesting date."}],"balance_after":20000,"derivative":{"exercise_price":49.74,"expiration_date":"2030-05-21","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001104659-20-065873","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1256126/000110465920065873/a4.xml","form_type":"4"}},{"id":3270160,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-02-14T16:25:40.000Z","date":"2018-07-02","kind":"gift","acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Family Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held by the Peter Mueller 2018 Irrevocable Family Trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the trust."}],"balance_after":90000,"source":{"system":"sec-edgar","filing":"0001104659-20-021807","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1256126/000110465920021807/a4.xml","form_type":"4"}},{"id":3270159,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-02-14T16:25:40.000Z","date":"2018-07-02","kind":"gift","acquired":false,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Number of shares held following the reported transaction reflects 41,475 shares of common stock that were inadvertently omitted from the reporting person's Form 3 filed on March 7, 2018."}],"balance_after":119795,"source":{"system":"sec-edgar","filing":"0001104659-20-021807","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1256126/000110465920021807/a4.xml","form_type":"4"}},{"id":3429099,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-08-26T17:38:04.000Z","date":"2019-08-23","kind":"purchase","acquired":true,"shares":1554,"price":9.34,"value":14514.36,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were acquired in multiple transactions at prices ranging from $9.09 to $9.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote."}],"balance_after":168320,"source":{"system":"sec-edgar","filing":"0001104659-19-047308","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1256126/000110465919047308/a4.xml","form_type":"4"}},{"id":3429978,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-08-23T16:26:47.000Z","date":"2019-08-22","kind":"purchase","acquired":true,"shares":6646,"price":8.83,"value":58684.18,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were acquired in multiple transactions at prices ranging from $8.43 to $9.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the SEC, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote."}],"balance_after":166766,"source":{"system":"sec-edgar","filing":"0001104659-19-047150","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1256126/000110465919047150/a4.xml","form_type":"4"}},{"id":3429977,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-08-23T16:26:47.000Z","date":"2019-08-21","kind":"purchase","acquired":true,"shares":1800,"price":8.42,"value":15156.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were acquired in multiple transactions at prices ranging from $8.29 to $8.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote."}],"balance_after":160120,"source":{"system":"sec-edgar","filing":"0001104659-19-047150","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1256126/000110465919047150/a4.xml","form_type":"4"}},{"id":3510068,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-05-28T21:00:19.000Z","date":"2019-05-23","kind":"grant","acquired":true,"shares":14700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full and become exercisable on the first anniversary of the grant date."}],"balance_after":14700,"derivative":{"exercise_price":10.04,"expiration_date":"2029-05-23","underlying":"Common Stock","underlying_shares":14700},"source":{"system":"sec-edgar","filing":"0001104659-19-032142","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1256126/000110465919032142/a4.xml","form_type":"4"}},{"id":3739141,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-12-07T17:50:40.000Z","date":"2018-12-07","kind":"purchase","acquired":true,"shares":6905,"price":5.01,"value":34594.05,"ownership":{"direct":true},"balance_after":158320,"source":{"system":"sec-edgar","filing":"0001104659-18-071881","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1256126/000110465918071881/a4.xml","form_type":"4"}},{"id":3739140,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-12-07T17:50:40.000Z","date":"2018-12-07","kind":"purchase","acquired":true,"shares":495,"price":5,"value":2475.0,"ownership":{"direct":true},"balance_after":151415,"source":{"system":"sec-edgar","filing":"0001104659-18-071881","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1256126/000110465918071881/a4.xml","form_type":"4"}},{"id":3739139,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-12-07T17:50:40.000Z","date":"2018-12-06","kind":"purchase","acquired":true,"shares":100,"price":5.01,"value":501.0,"ownership":{"direct":true},"balance_after":150920,"source":{"system":"sec-edgar","filing":"0001104659-18-071881","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1256126/000110465918071881/a4.xml","form_type":"4"}},{"id":3739138,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-12-07T17:50:40.000Z","date":"2018-12-06","kind":"purchase","acquired":true,"shares":1295,"price":5,"value":6475.0,"ownership":{"direct":true},"balance_after":150820,"source":{"system":"sec-edgar","filing":"0001104659-18-071881","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1256126/000110465918071881/a4.xml","form_type":"4"}},{"id":3740930,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-12-06T17:34:26.000Z","date":"2018-12-04","kind":"purchase","acquired":true,"shares":2062,"price":5.15,"value":10619.3,"ownership":{"direct":true},"balance_after":149525,"source":{"system":"sec-edgar","filing":"0001104659-18-071741","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1256126/000110465918071741/a4.xml","form_type":"4"}},{"id":3740929,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-12-06T17:34:26.000Z","date":"2018-12-04","kind":"purchase","acquired":true,"shares":200,"price":5.13,"value":1026.0,"ownership":{"direct":true},"balance_after":147463,"source":{"system":"sec-edgar","filing":"0001104659-18-071741","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1256126/000110465918071741/a4.xml","form_type":"4"}},{"id":3740928,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-12-06T17:34:26.000Z","date":"2018-12-04","kind":"purchase","acquired":true,"shares":344,"price":5.12,"value":1761.28,"ownership":{"direct":true},"balance_after":147263,"source":{"system":"sec-edgar","filing":"0001104659-18-071741","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1256126/000110465918071741/a4.xml","form_type":"4"}},{"id":3740927,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-12-06T17:34:26.000Z","date":"2018-12-04","kind":"purchase","acquired":true,"shares":325,"price":5.11,"value":1660.75,"ownership":{"direct":true},"balance_after":146919,"source":{"system":"sec-edgar","filing":"0001104659-18-071741","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1256126/000110465918071741/a4.xml","form_type":"4"}},{"id":3740926,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-12-06T17:34:26.000Z","date":"2018-12-04","kind":"purchase","acquired":true,"shares":1076,"price":5.09,"value":5476.84,"ownership":{"direct":true},"balance_after":146594,"source":{"system":"sec-edgar","filing":"0001104659-18-071741","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1256126/000110465918071741/a4.xml","form_type":"4"}},{"id":3997797,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2018-03-13T17:12:10.000Z","date":"2018-03-12","kind":"grant","acquired":true,"shares":37209,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this stock option vest as follows: one-third (12,403 shares) on each of 3/12/2019, 3/12/2020 and 3/12/2021."}],"balance_after":161397,"derivative":{"exercise_price":11,"expiration_date":"2028-03-12","underlying":"Common Stock","underlying_shares":37209},"source":{"system":"sec-edgar","filing":"0001104659-18-017148","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1256126/000110465918017148/a4.xml","form_type":"4"}},{"id":463945,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Stock Option (right to buy)","published_at":"2014-06-18T20:16:08.000Z","date":"2014-06-16","kind":"exercise","acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Fully vested."}],"balance_after":15500,"derivative":{"exercise_price":32.16,"expiration_date":"2018-07-23","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001209191-14-042313","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919114042313/doc4.xml","form_type":"4"}},{"id":463944,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Common Stock","published_at":"2014-06-18T20:16:08.000Z","date":"2014-06-16","kind":"sale","acquired":false,"shares":1000,"price":70.29,"value":70290.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Open market sales reported on this line occurred at a weighted average price of $70.29 (range $70.00 to $70.99)."}],"balance_after":143517,"source":{"system":"sec-edgar","filing":"0001209191-14-042313","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919114042313/doc4.xml","form_type":"4"}},{"id":463943,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Common  Stock","published_at":"2014-06-18T20:16:08.000Z","date":"2014-06-16","kind":"sale","acquired":false,"shares":597,"price":69.54,"value":41515.38,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Open market sales reported on this line occurred at a weighted average price of $69.54 (range $69.15 to $69.95)."}],"balance_after":144517,"source":{"system":"sec-edgar","filing":"0001209191-14-042313","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919114042313/doc4.xml","form_type":"4"}},{"id":463942,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Common Stock","published_at":"2014-06-18T20:16:08.000Z","date":"2014-06-16","kind":"sale","acquired":false,"shares":1500,"price":68.25,"value":102375.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $68.25 (range $68.04 to $68.86)."}],"balance_after":145114,"source":{"system":"sec-edgar","filing":"0001209191-14-042313","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919114042313/doc4.xml","form_type":"4"}},{"id":463941,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Common Stock","published_at":"2014-06-18T20:16:08.000Z","date":"2014-06-16","kind":"sale","acquired":false,"shares":4403,"price":67.72,"value":298171.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Open market sales reported on this line occurred at a weighted average price of $67.72 (range $67.47 to $67.96)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."}],"balance_after":146614,"source":{"system":"sec-edgar","filing":"0001209191-14-042313","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919114042313/doc4.xml","form_type":"4"}},{"id":463940,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Common Stock","published_at":"2014-06-18T20:16:08.000Z","date":"2014-06-16","kind":"exercise","acquired":true,"shares":7500,"price":32.16,"value":241200.0,"ownership":{"direct":true},"balance_after":151017,"source":{"system":"sec-edgar","filing":"0001209191-14-042313","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919114042313/doc4.xml","form_type":"4"}},{"id":464833,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Stock Option (right to buy)","published_at":"2014-05-16T20:06:30.000Z","date":"2014-05-14","kind":"exercise","acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Fully vested."}],"balance_after":23000,"derivative":{"exercise_price":32.16,"expiration_date":"2018-07-23","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001209191-14-034624","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919114034624/doc4.xml","form_type":"4"}},{"id":464832,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Common Stock","published_at":"2014-05-16T20:06:30.000Z","date":"2014-05-14","kind":"sale","acquired":false,"shares":600,"price":68.08,"value":40848.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Open market sales reported on this line occurred at a weighted average price of $68.08 (range $68.00 to $68.15)."}],"balance_after":143517,"source":{"system":"sec-edgar","filing":"0001209191-14-034624","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919114034624/doc4.xml","form_type":"4"}},{"id":464831,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Common Stock","published_at":"2014-05-16T20:06:30.000Z","date":"2014-05-14","kind":"sale","acquired":false,"shares":6400,"price":67.49,"value":431936.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $67.49 (range $67.02 to $67.90)."}],"balance_after":144117,"source":{"system":"sec-edgar","filing":"0001209191-14-034624","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919114034624/doc4.xml","form_type":"4"}},{"id":464830,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Common Stock","published_at":"2014-05-16T20:06:30.000Z","date":"2014-05-14","kind":"sale","acquired":false,"shares":500,"price":66.13,"value":33065.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Open market sales reported on this line occurred at a weighted average price of $66.13 (range $65.71 to $66.50)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."}],"balance_after":150517,"source":{"system":"sec-edgar","filing":"0001209191-14-034624","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919114034624/doc4.xml","form_type":"4"}},{"id":464829,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Common Stock","published_at":"2014-05-16T20:06:30.000Z","date":"2014-05-14","kind":"exercise","acquired":true,"shares":7500,"price":32.16,"value":241200.0,"ownership":{"direct":true},"balance_after":151017,"source":{"system":"sec-edgar","filing":"0001209191-14-034624","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919114034624/doc4.xml","form_type":"4"}},{"id":465776,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Stock Option (righty to buy)","published_at":"2014-04-17T20:12:48.000Z","date":"2014-04-15","kind":"exercise","acquired":false,"shares":5750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Fully vested."}],"balance_after":30500,"derivative":{"exercise_price":32.16,"expiration_date":"2018-07-23","underlying":"Common Stock","underlying_shares":5750},"source":{"system":"sec-edgar","filing":"0001209191-14-028131","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919114028131/doc4.xml","form_type":"4"}},{"id":465775,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Stock Option (right to buy)","published_at":"2014-04-17T20:12:48.000Z","date":"2014-04-15","kind":"exercise","acquired":false,"shares":1750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Fully vested."}],"balance_after":0,"derivative":{"exercise_price":28.84,"expiration_date":"2017-07-11","underlying":"Common Stock","underlying_shares":1750},"source":{"system":"sec-edgar","filing":"0001209191-14-028131","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919114028131/doc4.xml","form_type":"4"}},{"id":465774,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Common Stock","published_at":"2014-04-17T20:12:48.000Z","date":"2014-04-15","kind":"sale","acquired":false,"shares":700,"price":63.27,"value":44289.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Open market sales reported on this line occurred at a weighted average price of $63.27 (range $63.03 to $63.65)."}],"balance_after":158750,"source":{"system":"sec-edgar","filing":"0001209191-14-028131","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919114028131/doc4.xml","form_type":"4"}},{"id":465773,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Common Stock","published_at":"2014-04-17T20:12:48.000Z","date":"2014-04-15","kind":"sale","acquired":false,"shares":1800,"price":62.38,"value":112284.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Open market sales reported on this line occurred at a weighted average price of $62.38 (range $62.00 to $62.84)."}],"balance_after":159450,"source":{"system":"sec-edgar","filing":"0001209191-14-028131","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919114028131/doc4.xml","form_type":"4"}},{"id":465772,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Common Stock","published_at":"2014-04-17T20:12:48.000Z","date":"2014-04-15","kind":"sale","acquired":false,"shares":2900,"price":61.53,"value":178437.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $61.53 (range $61.05 to $61.97)."}],"balance_after":161250,"source":{"system":"sec-edgar","filing":"0001209191-14-028131","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919114028131/doc4.xml","form_type":"4"}},{"id":465771,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Common Stock","published_at":"2014-04-17T20:12:48.000Z","date":"2014-04-15","kind":"sale","acquired":false,"shares":2100,"price":60.57,"value":127197.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Open market sales reported on this line occurred at a weighted average price of $60.57 (range $60.06 to $60.94)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."}],"balance_after":164150,"source":{"system":"sec-edgar","filing":"0001209191-14-028131","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919114028131/doc4.xml","form_type":"4"}},{"id":465770,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Common Stock","published_at":"2014-04-17T20:12:48.000Z","date":"2014-04-15","kind":"exercise","acquired":true,"shares":5750,"price":32.16,"value":184920.0,"ownership":{"direct":true},"balance_after":166250,"source":{"system":"sec-edgar","filing":"0001209191-14-028131","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919114028131/doc4.xml","form_type":"4"}},{"id":465769,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Common Stock","published_at":"2014-04-17T20:12:48.000Z","date":"2014-04-15","kind":"exercise","acquired":true,"shares":1750,"price":28.84,"value":50470.0,"ownership":{"direct":true},"balance_after":160500,"source":{"system":"sec-edgar","filing":"0001209191-14-028131","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919114028131/doc4.xml","form_type":"4"}},{"id":466574,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Stock Option (right to buy)","published_at":"2014-03-19T20:16:51.000Z","date":"2014-03-17","kind":"exercise","acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Fully vested."}],"balance_after":1750,"derivative":{"exercise_price":28.84,"expiration_date":"2017-07-11","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001209191-14-021850","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919114021850/doc4.xml","form_type":"4"}},{"id":466573,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Common Stock","published_at":"2014-03-19T20:16:51.000Z","date":"2014-03-17","kind":"sale","acquired":false,"shares":1220,"price":78.78,"value":96111.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $78.78 (range $78.50 to $79.36)."}],"balance_after":158750,"source":{"system":"sec-edgar","filing":"0001209191-14-021850","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919114021850/doc4.xml","form_type":"4"}},{"id":466572,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Common Stock","published_at":"2014-03-19T20:16:51.000Z","date":"2014-03-17","kind":"sale","acquired":false,"shares":6280,"price":78.19,"value":491033.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Open market sales reported on this line occurred at a weighted average price of $78.19 (range $77.50 to $78.49)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."}],"balance_after":159970,"source":{"system":"sec-edgar","filing":"0001209191-14-021850","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919114021850/doc4.xml","form_type":"4"}},{"id":466571,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Common Stock","published_at":"2014-03-19T20:16:51.000Z","date":"2014-03-17","kind":"exercise","acquired":true,"shares":7500,"price":28.84,"value":216300.0,"ownership":{"direct":true},"balance_after":166250,"source":{"system":"sec-edgar","filing":"0001209191-14-021850","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919114021850/doc4.xml","form_type":"4"}},{"id":468350,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Stock Option (right to buy)","published_at":"2014-02-20T21:07:01.000Z","date":"2014-02-18","kind":"exercise","acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Fully vested."}],"balance_after":9250,"derivative":{"exercise_price":28.84,"expiration_date":"2017-07-11","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001209191-14-012316","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919114012316/doc4.xml","form_type":"4"}},{"id":468349,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Common Stock","published_at":"2014-02-20T21:07:01.000Z","date":"2014-02-18","kind":"sale","acquired":false,"shares":633,"price":83.05,"value":52570.65,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $83.05 (range $82.96 to $83.18)."}],"balance_after":158750,"source":{"system":"sec-edgar","filing":"0001209191-14-012316","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919114012316/doc4.xml","form_type":"4"}},{"id":468348,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Common Stock","published_at":"2014-02-20T21:07:01.000Z","date":"2014-02-18","kind":"sale","acquired":false,"shares":6867,"price":82.55,"value":566870.85,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Open market sales reported on this line occurred at a weighted average price of $82.55 (range $81.95 to $82.92)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."}],"balance_after":159383,"source":{"system":"sec-edgar","filing":"0001209191-14-012316","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919114012316/doc4.xml","form_type":"4"}},{"id":468347,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Common Stock","published_at":"2014-02-20T21:07:01.000Z","date":"2014-02-18","kind":"exercise","acquired":true,"shares":7500,"price":28.84,"value":216300.0,"ownership":{"direct":true},"balance_after":166250,"source":{"system":"sec-edgar","filing":"0001209191-14-012316","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919114012316/doc4.xml","form_type":"4"}},{"id":469335,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2014-02-07T21:06:18.000Z","date":"2014-02-05","kind":"grant","acquired":true,"shares":51000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in 16 quarterly installments from 02/05/2014."}],"balance_after":51000,"derivative":{"exercise_price":77.31,"expiration_date":"2024-02-04","underlying":"Common Stock","underlying_shares":51000},"source":{"system":"sec-edgar","filing":"0001209191-14-008356","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919114008356/doc4.xml","form_type":"4"}},{"id":469334,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Common Stock","published_at":"2014-02-07T21:06:18.000Z","date":"2014-02-05","kind":"grant","acquired":true,"shares":17250,"price":0.01,"value":172.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Stock grant under 2006 Stock and Option Plan, vesting on 2/5/2018, subject to (i) acceleration of 50% of shares upon (a) reaching a specified net product sales level over a one-year period for a combination regimen that includes ivacaftor and a CFTR corrector or (b) dosing of the first patient in the first clinical trial to evaluate a second-generation CFTR corrector compound and (ii) acceleration of 50% of shares upon (a) dosing of the first patient in a pivotal trial for a regimen including VX-661 or a specified cancer compound or (b) reaching a specified net product sales level over a one-year period for all our products."}],"balance_after":158750,"source":{"system":"sec-edgar","filing":"0001209191-14-008356","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919114008356/doc4.xml","form_type":"4"}},{"id":470325,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Stock Option (right to buy)","published_at":"2014-01-17T21:16:35.000Z","date":"2014-01-15","kind":"exercise","acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Fully vested."}],"balance_after":16750,"derivative":{"exercise_price":28.84,"expiration_date":"2017-07-11","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001209191-14-003731","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919114003731/doc4.xml","form_type":"4"}},{"id":470324,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Common Stock","published_at":"2014-01-17T21:16:35.000Z","date":"2014-01-15","kind":"sale","acquired":false,"shares":7500,"price":78.67,"value":590025.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Open market sales reported on this line occurred at a weighted average price of $78.67 (range $78.29 to $79.05)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."}],"balance_after":141500,"source":{"system":"sec-edgar","filing":"0001209191-14-003731","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919114003731/doc4.xml","form_type":"4"}},{"id":470323,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Common Stock","published_at":"2014-01-17T21:16:35.000Z","date":"2014-01-15","kind":"exercise","acquired":true,"shares":7500,"price":28.84,"value":216300.0,"ownership":{"direct":true},"balance_after":149000,"source":{"system":"sec-edgar","filing":"0001209191-14-003731","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919114003731/doc4.xml","form_type":"4"}},{"id":471196,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Stock Option (right to buy)","published_at":"2013-12-17T21:21:52.000Z","date":"2013-12-16","kind":"exercise","acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Fully vested."}],"balance_after":24250,"derivative":{"exercise_price":28.84,"expiration_date":"2017-07-11","underlying":"Common Stock","underlying_shares":4500},"source":{"system":"sec-edgar","filing":"0001209191-13-057361","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919113057361/doc4.xml","form_type":"4"}},{"id":471195,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Common Stock","published_at":"2013-12-17T21:21:52.000Z","date":"2013-12-16","kind":"sale","acquired":false,"shares":2100,"price":65.42,"value":137382.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $65.42 (range $64.95 to $66.46)."}],"balance_after":141500,"source":{"system":"sec-edgar","filing":"0001209191-13-057361","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919113057361/doc4.xml","form_type":"4"}},{"id":471194,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Common Stock","published_at":"2013-12-17T21:21:52.000Z","date":"2013-12-16","kind":"sale","acquired":false,"shares":5400,"price":64.4,"value":347760.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Open market sales reported on this line occurred at a weighted average price of $64.40 (range $63.94 to $64.83)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."}],"balance_after":143600,"source":{"system":"sec-edgar","filing":"0001209191-13-057361","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919113057361/doc4.xml","form_type":"4"}},{"id":471193,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Common Stock","published_at":"2013-12-17T21:21:52.000Z","date":"2013-12-16","kind":"exercise","acquired":true,"shares":7500,"price":28.84,"value":216300.0,"ownership":{"direct":true},"balance_after":149000,"source":{"system":"sec-edgar","filing":"0001209191-13-057361","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919113057361/doc4.xml","form_type":"4"}},{"id":471350,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Common Stock","published_at":"2013-12-12T22:51:06.000Z","date":"2013-12-12","kind":"sale","acquired":false,"shares":2900,"price":65.48,"value":189892.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Open market sales reported on this line occurred at a weighted average price of $65.48 (range $65.06 to $65.91)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."}],"balance_after":141500,"source":{"system":"sec-edgar","filing":"0001209191-13-056698","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919113056698/doc4.xml","form_type":"4"}},{"id":472456,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Stock Option (right to buy)","published_at":"2013-11-19T21:18:18.000Z","date":"2013-11-15","kind":"exercise","acquired":false,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Fully vested."}],"balance_after":31750,"derivative":{"exercise_price":28.84,"expiration_date":"2017-07-11","underlying":"Common Stock","underlying_shares":4500},"source":{"system":"sec-edgar","filing":"0001209191-13-053081","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919113053081/doc4.xml","form_type":"4"}},{"id":472455,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Stock Option (right to buy)","published_at":"2013-11-19T21:18:18.000Z","date":"2013-11-15","kind":"exercise","acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Fully vested."}],"balance_after":0,"derivative":{"exercise_price":18.93,"expiration_date":"2018-02-06","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001209191-13-053081","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919113053081/doc4.xml","form_type":"4"}},{"id":472454,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Common Stock","published_at":"2013-11-19T21:18:18.000Z","date":"2013-11-15","kind":"sale","acquired":false,"shares":2200,"price":63.12,"value":138864.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Open market sales reported on this line occurred at a weighted average price of $63.12 (range $63.02 to $63.26)."}],"balance_after":144400,"source":{"system":"sec-edgar","filing":"0001209191-13-053081","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919113053081/doc4.xml","form_type":"4"}},{"id":472453,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Common Stock","published_at":"2013-11-19T21:18:18.000Z","date":"2013-11-15","kind":"sale","acquired":false,"shares":4200,"price":62.62,"value":263004.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $62.62 (range $62.00 to $62.98)."}],"balance_after":146600,"source":{"system":"sec-edgar","filing":"0001209191-13-053081","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919113053081/doc4.xml","form_type":"4"}},{"id":472452,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Common Stock","published_at":"2013-11-19T21:18:18.000Z","date":"2013-11-15","kind":"sale","acquired":false,"shares":1100,"price":61.58,"value":67738.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Open market sales reported on this line occurred at a weighted average price of $61.58 (range $61.00 to $61.97)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."}],"balance_after":150800,"source":{"system":"sec-edgar","filing":"0001209191-13-053081","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919113053081/doc4.xml","form_type":"4"}},{"id":472451,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Common Stock","published_at":"2013-11-19T21:18:18.000Z","date":"2013-11-15","kind":"exercise","acquired":true,"shares":3000,"price":18.93,"value":56790.0,"ownership":{"direct":true},"balance_after":151900,"source":{"system":"sec-edgar","filing":"0001209191-13-053081","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919113053081/doc4.xml","form_type":"4"}},{"id":472450,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Common Stock","published_at":"2013-11-19T21:18:18.000Z","date":"2013-11-15","kind":"exercise","acquired":true,"shares":4500,"price":28.84,"value":129780.0,"ownership":{"direct":true},"balance_after":148900,"source":{"system":"sec-edgar","filing":"0001209191-13-053081","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919113053081/doc4.xml","form_type":"4"}},{"id":473586,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Stock Option","published_at":"2013-10-17T20:07:51.000Z","date":"2013-10-15","kind":"exercise","acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Fully vested."}],"balance_after":3000,"derivative":{"exercise_price":18.93,"expiration_date":"2018-02-06","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001209191-13-048645","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919113048645/doc4.xml","form_type":"4"}},{"id":473585,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Common Stock","published_at":"2013-10-17T20:07:51.000Z","date":"2013-10-15","kind":"sale","acquired":false,"shares":666,"price":73.85,"value":49184.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $73.85 (range $73.67 to $74.16)."}],"balance_after":144400,"source":{"system":"sec-edgar","filing":"0001209191-13-048645","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919113048645/doc4.xml","form_type":"4"}},{"id":473584,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Common Stock","published_at":"2013-10-17T20:07:51.000Z","date":"2013-10-15","kind":"sale","acquired":false,"shares":6834,"price":73.19,"value":500180.46,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Open market sales reported on this line occurred at a weighted average price of $73.19 (range $72.66 to $73.65)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."}],"balance_after":145066,"source":{"system":"sec-edgar","filing":"0001209191-13-048645","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919113048645/doc4.xml","form_type":"4"}},{"id":473583,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Common Stock","published_at":"2013-10-17T20:07:51.000Z","date":"2013-10-15","kind":"exercise","acquired":true,"shares":7500,"price":18.93,"value":141975.0,"ownership":{"direct":true},"balance_after":151900,"source":{"system":"sec-edgar","filing":"0001209191-13-048645","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919113048645/doc4.xml","form_type":"4"}},{"id":474292,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Stock Option","published_at":"2013-09-17T20:13:43.000Z","date":"2013-09-16","kind":"exercise","acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Fully vested."}],"balance_after":10500,"derivative":{"exercise_price":18.93,"expiration_date":"2018-02-06","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001209191-13-044599","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919113044599/doc4.xml","form_type":"4"}},{"id":474291,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Common Stock","published_at":"2013-09-17T20:13:43.000Z","date":"2013-09-16","kind":"sale","acquired":false,"shares":200,"price":79.08,"value":15816.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1."}],"balance_after":144400,"source":{"system":"sec-edgar","filing":"0001209191-13-044599","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919113044599/doc4.xml","form_type":"4"}},{"id":474290,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Common Stock","published_at":"2013-09-17T20:13:43.000Z","date":"2013-09-16","kind":"sale","acquired":false,"shares":1320,"price":78.38,"value":103461.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Open market sales reported on this line occurred at a weighted average price of $78.38 (range $78.03 to $78.89)."}],"balance_after":144600,"source":{"system":"sec-edgar","filing":"0001209191-13-044599","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919113044599/doc4.xml","form_type":"4"}},{"id":474289,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Common Stock","published_at":"2013-09-17T20:13:43.000Z","date":"2013-09-16","kind":"sale","acquired":false,"shares":2895,"price":77.44,"value":224188.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $77.44 (range $76.97 to $77.96)."}],"balance_after":145920,"source":{"system":"sec-edgar","filing":"0001209191-13-044599","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919113044599/doc4.xml","form_type":"4"}},{"id":474288,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Common Stock","published_at":"2013-09-17T20:13:43.000Z","date":"2013-09-16","kind":"sale","acquired":false,"shares":3085,"price":76.4,"value":235694.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Open market sales reported on this line occurred at a weighted average price of $76.40 (range $75.97 to $76.93)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."}],"balance_after":148815,"source":{"system":"sec-edgar","filing":"0001209191-13-044599","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919113044599/doc4.xml","form_type":"4"}},{"id":474287,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Common Stock","published_at":"2013-09-17T20:13:43.000Z","date":"2013-09-16","kind":"exercise","acquired":true,"shares":7500,"price":18.93,"value":141975.0,"ownership":{"direct":true},"balance_after":151900,"source":{"system":"sec-edgar","filing":"0001209191-13-044599","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919113044599/doc4.xml","form_type":"4"}},{"id":474965,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Stock Option","published_at":"2013-08-19T20:16:16.000Z","date":"2013-08-15","kind":"exercise","acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Fully vested."}],"balance_after":18000,"derivative":{"exercise_price":18.93,"expiration_date":"2018-02-06","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001209191-13-041331","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919113041331/doc4.xml","form_type":"4"}},{"id":474964,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Common Stock","published_at":"2013-08-19T20:16:16.000Z","date":"2013-08-15","kind":"sale","acquired":false,"shares":3000,"price":77.93,"value":233790.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $77.93 (range $77.67 to $78.21)."}],"balance_after":144400,"source":{"system":"sec-edgar","filing":"0001209191-13-041331","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919113041331/doc4.xml","form_type":"4"}},{"id":474963,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Common Stock","published_at":"2013-08-19T20:16:16.000Z","date":"2013-08-15","kind":"sale","acquired":false,"shares":4500,"price":77.06,"value":346770.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Open market sales reported on this line occurred at a weighted average price of $77.06 (range $76.69 to $77.66)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."}],"balance_after":147400,"source":{"system":"sec-edgar","filing":"0001209191-13-041331","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919113041331/doc4.xml","form_type":"4"}},{"id":474962,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Common Stock","published_at":"2013-08-19T20:16:16.000Z","date":"2013-08-15","kind":"exercise","acquired":true,"shares":7500,"price":18.93,"value":141975.0,"ownership":{"direct":true},"balance_after":151900,"source":{"system":"sec-edgar","filing":"0001209191-13-041331","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919113041331/doc4.xml","form_type":"4"}},{"id":475549,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Stock Option","published_at":"2013-08-01T20:11:57.000Z","date":"2013-07-30","kind":"grant","acquired":true,"shares":34000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in 16 quarterly installments from 07/30/2013."}],"balance_after":34000,"derivative":{"exercise_price":83.36,"expiration_date":"2023-07-29","underlying":"Common Stock","underlying_shares":34000},"source":{"system":"sec-edgar","filing":"0001209191-13-038688","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919113038688/doc4.xml","form_type":"4"}},{"id":475867,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Stock Option","published_at":"2013-07-17T20:38:53.000Z","date":"2013-07-15","kind":"exercise","acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Fully vested."}],"balance_after":25500,"derivative":{"exercise_price":18.93,"expiration_date":"2018-02-06","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001209191-13-037015","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919113037015/doc4.xml","form_type":"4"}},{"id":475866,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Common Stock","published_at":"2013-07-17T20:38:53.000Z","date":"2013-07-15","kind":"sale","acquired":false,"shares":2535,"price":86.66,"value":219683.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $86.66 (range $86.38 to $87.33)."}],"balance_after":144400,"source":{"system":"sec-edgar","filing":"0001209191-13-037015","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919113037015/doc4.xml","form_type":"4"}},{"id":475865,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Common Stock","published_at":"2013-07-17T20:38:53.000Z","date":"2013-07-15","kind":"sale","acquired":false,"shares":4965,"price":86.17,"value":427834.05,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Open market sales reported on this line occurred at a weighted average price of $86.17 (range $85.97 to $86.35)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."}],"balance_after":146935,"source":{"system":"sec-edgar","filing":"0001209191-13-037015","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919113037015/doc4.xml","form_type":"4"}},{"id":475864,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Common Stock","published_at":"2013-07-17T20:38:53.000Z","date":"2013-07-15","kind":"exercise","acquired":true,"shares":7500,"price":18.93,"value":141975.0,"ownership":{"direct":true},"balance_after":151900,"source":{"system":"sec-edgar","filing":"0001209191-13-037015","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919113037015/doc4.xml","form_type":"4"}},{"id":476133,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Stock Option","published_at":"2013-07-03T20:43:04.000Z","date":"2013-07-02","kind":"exercise","acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Fully vested."}],"balance_after":33000,"derivative":{"exercise_price":18.93,"expiration_date":"2018-02-06","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001209191-13-035485","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919113035485/doc4.xml","form_type":"4"}},{"id":476132,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Stock Option","published_at":"2013-07-03T20:43:04.000Z","date":"2013-07-02","kind":"exercise","acquired":false,"shares":9800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Fully vested."}],"balance_after":0,"derivative":{"exercise_price":16.32,"expiration_date":"2013-07-14","underlying":"Common Stock","underlying_shares":9800},"source":{"system":"sec-edgar","filing":"0001209191-13-035485","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919113035485/doc4.xml","form_type":"4"}},{"id":476131,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Stock Option","published_at":"2013-07-03T20:43:04.000Z","date":"2013-07-02","kind":"exercise","acquired":false,"shares":105000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Fully vested."}],"balance_after":195000,"derivative":{"exercise_price":33,"expiration_date":"2019-10-21","underlying":"Common Stock","underlying_shares":105000},"source":{"system":"sec-edgar","filing":"0001209191-13-035485","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919113035485/doc4.xml","form_type":"4"}},{"id":476130,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Common Stock","published_at":"2013-07-03T20:43:04.000Z","date":"2013-07-02","kind":"sale","acquired":false,"shares":39365,"price":80.58,"value":3172031.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Open market sales reported on this line occurred at a weighted average price of $80.58 (range $80.04 to $81.02)."}],"balance_after":144400,"source":{"system":"sec-edgar","filing":"0001209191-13-035485","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919113035485/doc4.xml","form_type":"4"}},{"id":476129,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Common Stock","published_at":"2013-07-03T20:43:04.000Z","date":"2013-07-02","kind":"sale","acquired":false,"shares":68985,"price":79.52,"value":5485687.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $79.52 (range $79.03 to $80.02)."}],"balance_after":183765,"source":{"system":"sec-edgar","filing":"0001209191-13-035485","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919113035485/doc4.xml","form_type":"4"}},{"id":476128,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Common Stock","published_at":"2013-07-03T20:43:04.000Z","date":"2013-07-02","kind":"sale","acquired":false,"shares":13950,"price":78.94,"value":1101213.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Open market sales reported on this line occurred at a weighted average price of $78.94 (range $78.82 to $79.02)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."}],"balance_after":252750,"source":{"system":"sec-edgar","filing":"0001209191-13-035485","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919113035485/doc4.xml","form_type":"4"}},{"id":476127,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Common Stock","published_at":"2013-07-03T20:43:04.000Z","date":"2013-07-02","kind":"exercise","acquired":true,"shares":7500,"price":18.93,"value":141975.0,"ownership":{"direct":true},"balance_after":266700,"source":{"system":"sec-edgar","filing":"0001209191-13-035485","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919113035485/doc4.xml","form_type":"4"}},{"id":476126,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Common Stock","published_at":"2013-07-03T20:43:04.000Z","date":"2013-07-02","kind":"exercise","acquired":true,"shares":9800,"price":16.32,"value":159936.0,"ownership":{"direct":true},"balance_after":259200,"source":{"system":"sec-edgar","filing":"0001209191-13-035485","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919113035485/doc4.xml","form_type":"4"}},{"id":476125,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Common Stock","published_at":"2013-07-03T20:43:04.000Z","date":"2013-07-02","kind":"exercise","acquired":true,"shares":105000,"price":33,"value":3465000.0,"ownership":{"direct":true},"balance_after":249400,"source":{"system":"sec-edgar","filing":"0001209191-13-035485","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919113035485/doc4.xml","form_type":"4"}},{"id":477604,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Common Stock","published_at":"2013-05-20T20:22:22.000Z","date":"2013-05-16","kind":"gift","acquired":false,"shares":10352,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Shares held by GRATS"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"On May 16, 2013, grantor retained annuity trusts (GRATS) established by Dr. Mueller in 2010 that held 15,920 shares of common stock terminated in accordance with the terms of the GRATs.  10,352 shares were transferred to  a trust established for the benefit of Dr. Mueller's adult child.  The remaining 5,568 shares were distributed to revocable trusts established for the benefit of Dr. Mueller and his wife and are reported on this Form 4 as indirectly owned."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-13-027552","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919113027552/doc4.xml","form_type":"4"}},{"id":482332,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2013-02-07T22:32:34.000Z","date":"2013-02-05","kind":"grant","acquired":true,"shares":54375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/05/2013."}],"balance_after":54375,"derivative":{"exercise_price":45.11,"expiration_date":"2023-02-04","underlying":"Common Stock","underlying_shares":54375},"source":{"system":"sec-edgar","filing":"0001209191-13-007128","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919113007128/doc4.xml","form_type":"4"}},{"id":482331,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Common Stock","published_at":"2013-02-07T22:32:34.000Z","date":"2013-02-05","kind":"grant","acquired":true,"shares":12084,"price":0.01,"value":120.84,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Stock grant under 2006 Stock and Option Plan, vesting on 2/5/2017, subject to (i) acceleration of 50% of shares upon (a) receiving filing confirmation for an NDA for a combination regimen that includes both ivacaftor and a corrector compound or (b) receiving filing confirmation for an sNDA that would increase the number of patients with CF eligible for ivacaftor monotherapy, and (ii) acceleration of 50% of shares upon (a) the announcement of proof-of-concept data for a drug candidate other than an HCV, cystic fibrosis, influenza or JAK3 inhibition drug candidate or (b) reaching a specified net sales level over a twelve month period for our CF products."}],"balance_after":144400,"source":{"system":"sec-edgar","filing":"0001209191-13-007128","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919113007128/doc4.xml","form_type":"4"}},{"id":487191,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Employee Stock Option Grant (right to buy)","published_at":"2012-10-16T20:43:45.000Z","date":"2012-10-15","kind":"exercise","acquired":false,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Fully vested."}],"balance_after":9800,"derivative":{"exercise_price":16.32,"expiration_date":"2013-07-14","underlying":"Common Stock","underlying_shares":6500},"source":{"system":"sec-edgar","filing":"0001209191-12-049586","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919112049586/doc4.xml","form_type":"4"}},{"id":487190,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global R&D, CSO"}}],"security":"Common Stock","published_at":"2012-10-16T20:43:45.000Z","date":"2012-10-15","kind":"sale","acquired":false,"shares":2000,"price":53.14,"value":106280.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $53.14 (range $53.00 to $53.91)."}],"balance_after":132316,"source":{"system":"sec-edgar","filing":"0001209191-12-049586","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919112049586/doc4.xml","form_type":"4"}}],"next_cursor":"2012-10-16T20:43:45.000000Z,487190"}